Pharmaceuticals & Therapeutics

A new survey reveals the crippling cost of insulin, forcing millions to choose between medicine and groceries. A bipartisan bill may offer a lifeline.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

The European Commission has approved MAVIRET for acute Hepatitis C, a move set to streamline patient care and accelerate progress against a silent epidemic.

AbbVie's blockbuster SKYRIZI wins European approval for pediatric psoriasis, unlocking a new market and offering a new standard of care to young patients.

Ottawa's quiet $892K investment in a Vancouver biotech firm is more than a grant; it's a calculated move to secure Canada's food supply from a post-antibiotic crisis.

A decade of new science has prompted the FDA to overhaul testosterone therapy rules, erasing old fears and unlocking a multi-billion dollar market for aging men.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

Praxis Precision Medicines' elsunersen earns Breakthrough Therapy status, signaling a major step toward the first disease-modifying treatment for SCN2A-DEE.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

Merck's positive Phase 3 results for tulisokibart signal a new era for UC care, targeting both fibrosis and inflammation in a potential first-in-class win.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

Alberta is launching a controversial private healthcare option, promising efficiency. Critics warn it's a two-tier system that will let the rich jump the queue.

A new partnership between Pirche and Natera promises to connect pre-transplant risk analysis with post-transplant monitoring, ushering in an era of truly personalized care.

Ottawa's new asylum regulations promise speed and order, but critics warn of eroded protections. A deep dive into the strategy behind the reforms.

For Northern Nevada homeowners, a failing water heater is more than an inconvenience; it's a critical investment decision influenced by harsh local conditions.

Dr. Ruth J. Simmons' tribute to her sister at Texas Southern University is more than a donation; it's a strategic model for tackling deep-seated health disparities.

A new index reveals pharma's $8B ad spend fails to buy AI visibility. Eli Lilly and Novo Nordisk lead as AI follows patient research, not TV spots.

A looming federal announcement signals a major push for nuclear energy. This isn't just about climate goals; it's a commercialization roadmap for a new era.

A major partnership in Michigan and Ohio's ENT sector signals a growing trend: private equity-backed groups are reshaping independent medical practices.